Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 4387 results
Scientists identify how cancer cells can shrug off physical constraints on growth and spread
Scientists have revealed how cancer cells are able to break free of the physical restraints imposed by their surroundings in order to grow and spread around the body.
Drug Research > Drug Discovery & Development > News
APT Therapeutics partners with AstraZeneca for human apyrase therapy
APT Therapeutics has signed a research collaboration, option and asset purchase agreement with AstraZeneca.
Drug Research > Drug Discovery & Development > News
Ascletis completes $100m Series B Financing
Ascletis, a biotechnology company engaged in the discovery, development and commercialization of new treatments for liver diseases, has raised $100m in series B financing.
Drug Research > Drug Discovery & Development > News
BiondVax secures $2.8m investment from Marius Nacht fund
By PBR Staff Writer
Angels High Tech Investments has agreed to invest $2.8m in BiondVax Pharmaceuticals, a company which is engaged in the development of a universal flu vaccine.
Drug Research > Drug Discovery & Development > News
Incyte, Merus partner to discover bispecific antibodies
Incyte and Merus have forged a global, strategic collaboration agreement on the research, discovery and development of bispecific antibodies utilizing Merus’ Biclonics technology platform.
Drug Research > Drug Discovery & Development > News
Novartis agrees to acquire Encore Vision
Novartis has agreed to acquire Encore Vision, a privately-held firm in Fort Worth, Texas, US, engaged in the development of a novel treatment in presbyopia.
Drug Research > Drug Discovery & Development > News
X-Chem, Taiho establish multi-target drug discovery collaboration
X-Chem has entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical.
Drug Research > Drug Discovery & Development > News
Novartis partners with Conatus on new oral treatments for chronic liver diseases
By PBR Staff Writer
Swiss pharma giant Novartis is collaborating with US biotechnology firm Conatus Pharmaceuticals on the development of new oral treatments for chronic liver diseases.
Drug Research > Drug Discovery & Development > News
Evotec, Celgene partner to identify neurodegenerative disease candidates
Evotec and Celgene have entered into a drug discovery and development collaboration to identify disease-modifying therapeutics for a range of neurodegenerative diseases.
Drug Research > Drug Discovery & Development > News
Novartis to acquire Ziarco to expand dermatology portfolio
Novartis has agreed to acquire Ziarco Group, a privately held firm engaged in the development of novel treatments in dermatology.
Drug Research > Drug Discovery & Development > News
Lonza agrees to acquire Capsugel for $5.5bn
By PBR Staff Writer
Swiss pharmaceutical firm Lonza has agreed to acquire US drug capsules manufacturer Capsugel from Kohlberg Kravis Roberts (KKR) for $5.5bn in cash.
Drug Research > Drug Discovery & Development > News
Third Rock launches Goldfinch Bio for kidney disease work
Third Rock Ventures has launched Goldfinch Bio, a company focused on the discovery and development of precision therapies for patients with kidney disease.
Drug Research > Drug Discovery & Development > News
Bayer, Versant Ventures invest $225m in new stem cell therapy company
By PBR Staff Writer
Bayer and health care investment firm Versant Ventures are investing $225m in a new stem cell therapy company, BlueRock Therapeutics.
Drug Research > Drug Discovery & Development > News
Forge Therapeutics, Evotec establish superbug alliance
Forge Therapeutics has partnered with Evotec to advance its novel Gram-negative antibiotic program targeting ‘LpxC’ to treat bacterial infections including those caused by drug resistant superbugs.
Drug Research > Drug Discovery & Development > News
Bicycle, AstraZeneca enter into potential $1bn multitarget collaboration
By PBR Staff Writer
Bicycle Therapeutics and AstraZeneca have agreed a $1bn multi-target collaboration across respiratory, cardiovascular and metabolic diseases.
Drug Research > Drug Discovery & Development > News
61-75 of 4387 results